IMP1734
Phase 1/2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor
Trial Timeline
Dec 11, 2023 → Dec 1, 2027
NCT ID
NCT06253130About IMP1734
IMP1734 is a phase 1/2 stage product being developed by Eikon Therapeutics for Advanced Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06253130. Target conditions include Advanced Solid Tumor.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06253130 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumor